Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O0JP
|
|||
| Former ID |
DIB000730
|
|||
| Drug Name |
EMA-401
|
|||
| Synonyms |
Neuropathic pain targeting small molecules (postherpetic neuralgia), Spinifex
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Peripheral neuropathy [ICD-11: 8C0Z] | Phase 2 | [1] | |
| Postherpetic neuralgia [ICD-11: 1E91.5; ICD-10: G53.0; ICD-9: 53.19] | Phase 2 | [2], [3] | ||
| Company |
Spinifex pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C32H29NO5
|
|||
| Canonical SMILES |
COC1=C(C2=C(CN(C(C2)C(=O)O)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4)C=C1)OCC5=CC=CC=C5
|
|||
| InChI |
1S/C32H29NO5/c1-37-28-18-17-25-20-33(31(34)29(23-13-7-3-8-14-23)24-15-9-4-10-16-24)27(32(35)36)19-26(25)30(28)38-21-22-11-5-2-6-12-22/h2-18,27,29H,19-21H2,1H3,(H,35,36)/t27-/m0/s1
|
|||
| InChIKey |
GHBCIXGRCZIPNQ-MHZLTWQESA-N
|
|||
| CAS Number |
CAS 1316755-16-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiotensin II receptor type-2 (AGTR2) | Target Info | Antagonist | [4] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Adrenergic signaling in cardiomyocytes | ||||
| Renin-angiotensin system | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | ACE Inhibitor Pathway | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8374). | |||
| REF 3 | ClinicalTrials.gov (NCT02435199) Clinical Trial Designed to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy. U.S. National Institutes of Health. | |||
| REF 4 | Clinical pipeline report, company report or official report of Spinifex. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.